Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Not Yet Opened 07-23 16:00:00 EDT

39.37

+0.32

+0.82%

盘后39.37

+0.000.00%

19:34 EDT

High39.60	Low38.00	Vol784.11K
Open38.39	D1 Closing39.05	Amplitude4.10%
Mkt Cap8.08B	Tradable Cap3.10B	Total Shares205.31M
T/O30.73M	T/O Rate1.00%	Tradable Shares78.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":39.37,"timestamp":1784836800000,"preClose":39.05,"halted":0,"volume":784113,"hourTrading":{"tag":"盘后","latestPrice":39.37,"preClose":39.37,"latestTime":"19:34 EDT","volume":34135,"amount":1343894.96,"timestamp":1784849649443,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00819462227912933,"floatShares":78746500,"shares":205308917,"eps":-2.77164,"marketStatus":"Not Yet Opened","change":0.32,"latestTime":"07-23 16:00:00 EDT","open":38.39,"high":39.6,"low":38,"amount":30730182.776469,"amplitude":0.040973,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.77164,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784880000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":39.05,"preHourTrading":{"tag":"盘前","latestPrice":38.45,"preClose":39.05,"latestTime":"09:29 EDT","volume":3275,"amount":126907.37332500001,"timestamp":1784813399999,"change":-0.6,"changeRate":-0.015365,"amplitude":0.056338},"postHourTrading":{"tag":"盘后","latestPrice":39.37,"preClose":39.37,"latestTime":"19:34 EDT","volume":34135,"amount":1343894.96,"timestamp":1784849649443,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.85259,"impliedVol":0.523,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/IMVT/tweets","defaultTab":"tweets","newsList":[{"id":"2653490775","title":"Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490775","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653490775?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838369,"startTime":"0","endTime":"0","summary":"Immunovant updates financial calendar with first-quarter results release and business update callImmunovant to report fiscal Q1 results for the period ended June 30, 2026 on Aug. 6, 2026, before the m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL78ZZLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","ROIV","LU2095319765.USD","BK4007","PTH","IE00B3QW5Z07.USD","BCDF","SG9999014021.USD","NDAQ","BK4585","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4139","BK4112","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653979877","title":"Immunovant Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653979877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653979877?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:11","pubTimestamp":1784751092,"startTime":"0","endTime":"0","summary":"Immunovant announces annual shareholder meetingImmunovant will hold its annual stockholders meeting virtually on Sept. 2, 2026.Shareholders will vote on electing three directors: Jacob Bauer, Douglas ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5k6tVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IMVT","BK4139","ROIV","BK4007","PTH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867102","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649867102?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:02","pubTimestamp":1783371732,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $3.46 millionImmunovant CEO Eric Venker acquired 92,188 common shares on July 1, 2026 at $14.46 per share.He disposed of 86,629 shares on Jul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLj4h1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PTH","IMVT","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648681288","title":"Chief Technology Officer Of Immunovant Sold 53% Of Their Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648681288","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648681288?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:48","pubTimestamp":1783007321,"startTime":"0","endTime":"0","summary":"Some Immunovant, Inc. ( NASDAQ:IMVT ) shareholders may be a little concerned to see that the Chief Technology Officer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/chief-technology-officer-of-immunovant-sold-53-of-their-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/chief-technology-officer-of-immunovant-sold-53-of-their-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648756602","title":"Immunovant is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2648756602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648756602?lang=en_us&edition=fundamental","pubTime":"2026-07-01 02:59","pubTimestamp":1782845940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 14:59 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IMVT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537434","title":"Immunovant price target raised to $61 from $57 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537434?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816009,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Immunovant (IMVT) to $61 from $57 and keeps a Buy rating on the shares. Published first on TheFly – the ulti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-61-from-57-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-61-from-57-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646974395","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015","url":"https://stock-news.laohu8.com/highlight/detail?id=2646974395","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646974395?lang=en_us&edition=fundamental","pubTime":"2026-06-27 07:43","pubTimestamp":1782517435,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $57,015Immunovant director Atul Pande exercised stock options for 1,500 common shares at $8.43 on June 26, 2026.Pande sold 1,500 comm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLSyS6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4588","ROIV","BK4585","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393286","title":"Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393286","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393286?lang=en_us&edition=fundamental","pubTime":"2026-06-27 06:14","pubTimestamp":1782512070,"startTime":"0","endTime":"0","summary":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of common shares worth $6.63 millionRoivant Sciences President and Immunovant CEO Eric Venker exercised stock options for 200,000 com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL3gJsLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","ROIV","BK4139","IMVT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354688","title":"S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646354688?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:30","pubTimestamp":1782473400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Immunovant Inc. (IMVT) was up 9.2% in pre-market trad","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPYQ","IJH","DGRO","SPXS","FDN","SMAX","UPRO","DOG","LU2360107325.USD","IE00BD6J9T35.USD","BK4605","BK4585","DGRW","LU1861214812.USD","DMAX","SCHB","LU1978683503.SGD","ROAD","LU1983260115.SGD","VV","SPYD","LU1854103824.USD","SCHX","SCHG","YMAX","LU0348723411.USD","SPDN","SSO","UDOW","VYMI","GRNY","DDM","MGK","LU1720051108.HKD","XLI","DJX","SPYU","SPXL","BMAY","TSPY","BK4129","BK4196","FDVV","IMVT","BK4588","LU1854104046.USD","BK4559","SH","DJIA","IE0031619046.USD","RSPA","ETFT","LU1169590202.USD","SDY","IVW","VBK","ITOT","TOPT","RSPN","XDTE","NOBL","HIBS","SFY","IVE","IVV","LU2357305700.SGD","MYMmain","LU1861220033.SGD","GPIX","DXD","VUG","VEU","IE00BZ199S13.USD","BK4139","ACWI","DIA","BIO","SDS","IE00B7SZL793.SGD","DVY","SPYM","HIBL","SPMO","BK4121","RSP","SPYG","VYM","SPUU","RSPU","SDOW","IE00B19Z4B17.USD","JEPI","IJR","LU1861215975.USD","LU1548497426.USD","SPYV","XLG","ON","IE00BFMHRM44.USD","MOAT","SPUS","MMAX","BK4505","LU0124384867.USD","YSPY","LU1169589451.USD","SPHD","GSLC","VTV","BK4141","DBSC","SPHQ","SPLV","BK4512","LU0724618433.USD","VTI","LU1720051017.SGD","SCHD","SPGP","SPYH","SPXU","XYLD","ALLW","DVA","IE00B66KJ199.SGD","CYTK","LU1861219969.SGD","LU2298322129.HKD",".DJI",".SPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644789030","title":"Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2644789030","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644789030?lang=en_us&edition=fundamental","pubTime":"2026-06-19 10:36","pubTimestamp":1781836585,"startTime":"0","endTime":"0","summary":"In recent days, Immunovant reported that its FcRn inhibitor Batoclimab achieved clinically meaningful improvements in a Phase IIb trial for chronic inflammatory demyelinating polyneuropathy (CIDP), supporting its potential use in this difficult autoimmune condition. \nThis progress in CIDP adds another possible indication to Immunovant’s FcRn pipeline, deepening its footprint in autoimmune neurology alongside a crowded field of emerging competitors.\nNext, we’ll examine how Batoclimab’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-is-up-75-after-batoclimab-shows-phase-iib-ci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-is-up-75-after-batoclimab-shows-phase-iib-ci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","BK4585","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767441","title":"Immunovant director Atul Pande disposes of USD 51,030 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767441","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767441?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:03","pubTimestamp":1781640228,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande sold 1,500 shares on June 15, 2026 at USD 34.02.He also acquired 1,500 shares the same day via option exercise at USD 8.43.Derivative holdings included 69,681 stock options following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6VlcnR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","ROIV","IMVT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642738744","title":"A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2642738744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642738744?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:16","pubTimestamp":1781111815,"startTime":"0","endTime":"0","summary":"Recent commentary on high response rates and full enrollment in Immunovant (IMVT)'s Phase 2 rheumatoid arthritis trial for IMVT-1402 has focused investor attention on whether this engagement in a difficult-to-treat population justifies the stock’s recent momentum.\nSee our latest analysis for Immunovant.\nThat trial update lands on top of solid momentum in the stock, with a 30 day share price return of 9.23% and a 1 year total shareholder return of 88.83%. This points to building enthusiasm...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/a-look-at-immunovant-imvt-valuation-as-imvt-1402-trial-engag","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/a-look-at-immunovant-imvt-valuation-as-imvt-1402-trial-engag","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641179545","title":"Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641179545","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641179545?lang=en_us&edition=fundamental","pubTime":"2026-06-08 01:13","pubTimestamp":1780852390,"startTime":"0","endTime":"0","summary":"Recent commentary on Immunovant’s IMVT-1402 program highlighted high response rates in a completed Phase 2 rheumatoid arthritis trial, including in patients who had already received multiple advanced therapies.\nThis focus on difficult-to-treat patients has pushed IMVT-1402 to the center of Immunovant’s story, raising questions about how such response rates could shape expectations for its broader autoimmune pipeline.\nWe’ll now look at how the strong IMVT-1402 Phase 2 responses in difficult...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4588","BK4585","BK4139","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639260672","title":"Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2639260672","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639260672?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:05","pubTimestamp":1780085153,"startTime":"0","endTime":"0","summary":"Immunovant director Andrew J. Fromkin sold 221,951 shares on May 28, 2026 at weighted-average prices of $32.64 and $33.56.He exercised stock options for 196,601 shares the same day at exercise prices ranging from $4.99 to $14.7.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL1j1p0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMVT","BK4585","BK4588","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639671598","title":"Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2639671598","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639671598?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:06","pubTimestamp":1780070776,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has been drawing attention after recent share price moves, with the stock up about 24% over the past month and about 21% over the past 3 months, prompting closer scrutiny from biotech investors.\nSee our latest analysis for Immunovant.\nAt the current share price of US$33.50, Immunovant’s recent 30 day share price return of 24.12% and year to date share price return of 29.29% sit alongside a 1 year total shareholder return of 124.98%. This indicates strong momentum over both...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-recent-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638642517","title":"Immunovant Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638642517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638642517?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:06","pubTimestamp":1779800760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 09:06 ET (13:06 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515256","title":"H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515256","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515256?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:37","pubTimestamp":1779791861,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Immunovant, with a price target of $40.00. According to Ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347691","title":"Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347691","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347691?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:26","pubTimestamp":1779488781,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker reported the sale of 200,000 common shares on May 22 at a weighted average price of $30.27.He also exercised stock options for 200,000 common shares on May 22 at $3.85.Venker disposed of 34,483 common shares on May 20 at $32.41.He held 1,613,063 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8bLkBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IMVT","ROIV","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343745","title":"Immunovant Is Maintained at Hold by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343745","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637343745?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:51","pubTimestamp":1779465060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2026 11:51 ET (15:51 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637430310","title":"Immunovant price target raised to $30 from $23 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2637430310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637430310?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:20","pubTimestamp":1779459605,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $30 from $23 and keeps a Hold rating on the shares. The firm i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-30-from-23-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-30-from-23-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IMVT","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0249},{"period":"3month","weight":0.3507},{"period":"6month","weight":0.5013},{"period":"1year","weight":1.1767},{"period":"ytd","weight":0.5362}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.03708},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction